US FDA Staff Mixed on AstraZeneca PLC Drug, Brilinta

July 27, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Reuters -- U.S. reviewers gave mixed views on AstraZeneca Plc’s (AZN.L) experimental blood thinner but the company’s shares rose on investor optimism that an advisory panel will back the potential blockbuster drug.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

AstraZeneca Pharmaceuticals LP Food and Drug Administration (FDA)